SkyePharma lays off 20 at research center; Aeras to collaborate with China National on TB vaccines;

@FierceBiotech: Merck's head dealmaker Pomerantz says his co. "will do what it takes" to lead race for hep C combo therapies. Story | Follow @FierceBiotech

@JohnCFierce: Canaan Partners adds $200M in venture funds for life sciences. More | Follow @JohnCFierce

@MarkHFierce: St. Jude ($STJ) expects to launch a second-generation neuromodulation treatment for some migraines in Europe in Q2 2012--"a big growth driver." | Follow @MarkHFierce

@MaureenFierce: Wake Forest kicks off PhII study of ICT-107, a brain cancer vaccine that "acts like bloodhound to locate cancer cells." Article | Follow @MaureenFierce

@RyanMFierce: Check out @Reuters graphic on shrinking DNA sequencing costs. Nothing really new in there, but remarkable. Graphic | Follow @RyanMFierce

> SkyePharma says it will cut about 20 workers at its research center in Switzerland.  Aenova plans to sublet part of the space and may hire a few of the workers who are being laid off. Story

> Rockville, MD-based Aeras and the China National Biotec Group struck a deal to jointly develop new tuberculosis vaccines. Release

> Switzerland's Telormedix, which has been working on TLR7 agonists in the treatment of cancer and inflammatory diseases, raised 7.5 million CHF from existing investors Aravis Venture and Proquest Investments. Release

> Cambridge, MA-based Epizyme scored a $4 million milestone in its alliance with Eisai. Release

Pharma News

@FiercePharma: From WSJ, a nice look at the shift in #pharma sales strategies, now that 33K reps have seen the ax. Article | Follow @FiercePharma

> FDA: Endo opioids may be mixed in Novartis OTC packages. Report

> Lilly's Lechleiter sees pharma clouds abroad. Story

> Study flags risk of heart attack, ACS in Pradaxa patients. Article

Biotech Research News

> Genetic mutations discovered in non-smoking lung cancer patients. Article

> Low-intensity electromagnetic fields shrink liver cancer tumors. More

> Breakthrough trial protects monkeys from HIV-like virus. Story

> Scientists deduce gene that may contribute to major depression. News

> Injection of young stem cells boosts vitality in prematurely aging mice. Piece

Manufacturing News

> Novartis recall hints at regulatory snowball. More

> Parents allege J&J's excess-API Tylenol killed son. Story

> USP suits up for pedigree challenge. Article

> Genzyme's new plant to boost Fabrazyme supply. News

> Xoma cuts manufacturing to feed R&D. Story

And Finally... Chinese officials say they're putting a stop to the unauthorized and possibly dangerous use of stem cell treatments in the country. Report

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.